L3VLUP
ProSign in

IDYA · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

IDYALLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • IDYA
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterIDYALLY
Q3 20201 holders, $15m33 holders, $14.1bn
Q4 20201 holders, $16m29 holders, $17.3bn
Q1 20213 holders, $31m24 holders, $23.0bn
Q2 20213 holders, $26m24 holders, $27.8bn
Q3 20213 holders, $37m31 holders, $29.9bn
Q4 20213 holders, $50m31 holders, $34.7bn
Q1 20221 holders, $21m24 holders, $35.3bn
Q2 20221 holders, $21m33 holders, $42.7bn
Q3 2022none listed holders, n.a.31 holders, $43.4bn
Q4 2022none listed holders, n.a.31 holders, $46.6bn
Q1 2023none listed holders, n.a.33 holders, $44.3bn
Q2 20233 holders, $60m37 holders, $59.6bn
Q3 20234 holders, $118m44 holders, $67.6bn
Q4 20235 holders, $275m45 holders, $73.6bn
Q1 202410 holders, $1.0bn41 holders, $95.3bn
Q2 20248 holders, $479m43 holders, $110bn
Q3 20246 holders, $309m45 holders, $107bn
Q4 20245 holders, $245m46 holders, $93.9bn
Q1 20253 holders, $159m42 holders, $98.4bn
Q2 20253 holders, $374m43 holders, $93.2bn
Q3 20254 holders, $458m39 holders, $86.7bn
Q4 20253 holders, $495m41 holders, $123bn
Q1 20262 holders, $414m39 holders, $106bn
Q2 20263 holders, $533m44 holders, $132bn
IDYA

Ideaya Biosciences Inc

Holders
10
Reported value
$1.0bn
Buyers
8
Sellers
1

Breadth +7 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
41
Reported value
$95.3bn
Buyers
15
Sellers
27

Breadth -12 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 43 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only IDYA (2)

Farallon Capital Management LLC, Hudson Bay Capital Management LP

Only LLY (33)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, GAMCO Investors Inc, Invesco Ltd, Jane Street Group LLC, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Moore Capital Management LP, Neuberger Berman Group LLC, Point72 Asset Management LP, Polen Capital Management LLC, Renaissance Technologies LLC, and 8 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →